Skip to content

Evaluation of Clinical Perfectionism in Parkinson Disease

Evaluation of Clinical Perfectionism in Parkinson Disease

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02824367
Acronym
EPMP-1
Enrollment
59
Registered
2016-07-06
Start date
2014-10-06
Completion date
2017-08-25
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson, Perfectionism

Brief summary

Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety.

Detailed description

Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety. Also, clinicians reported that they exhibit specific personality traits (e.g., rigidity and perfectionism). To date, few studies used Cognitive Behavioural Therapies (CBT) in people with Parkinson's disease showing promising results. Recently, perfectionism has received particular attention because of it association with many emotional disorders. Thus, some psychometric tools have been developed in order to evaluate different aspects of perfectionism. Yet, none of them has been used in people with Parkinson's disease. The objective of this study is to investigate whether there is a direct link between Parkinson's disease and perfectionism by using psychometric tools from the CBT literature. Identifying such link would allow to justify the use of CBT in people with Parkinson's disease with the goal in mind to improve their care and quality of life.

Interventions

BEHAVIORALCompletion of scales evaluation

Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than 18 years * Score Mini Mental Scale (MMS) greater than 23 * For Parkinsonian, Parkinson disease be defined according to the criteria of the Unified Parkinson Disease Rating Scale (UPDRS), with a Hoehn and Yahr stage 1, 2 or 3 * The control patients present dystonias not within the scope of Parkinson * Informed Consent Form signed * Patient covered by social insurance

Exclusion criteria

* Proven Presence of neuropsychological disorders * Patients with deep brain stimulation * Diagnosis of somatic pathology diagnosed * Private Patient freedom or protected adult (under guardianship)

Design outcomes

Primary

MeasureTime frameDescription
Perfectionism evaluation 1Day 0Scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS)
Perfectionism evaluation 2Day 0Hewitt Multidimensional Perfectionism Scale (HMPS).

Secondary

MeasureTime frameDescription
Depression and anxiety evaluation 1Day 0Scores to depression scale (Beck Depression Inventory (BDI))
Depression and anxiety evaluation 2Day 0anxiety scale (State Trait Anxiety Inventory (STAI))

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPierre KRYSTKOWIAK, MD, PhD

CHU Amiens

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026